Surf Therapeutics Reports Positive First-in-Human Data and Secures Additional Financing, Bringing Total Funding to $6M as Rheumatoid Arthritis Clinical Study Begins [Yahoo! Finance]
Rani Therapeutics Holdings, Inc. - Class A (RANI)
Company Research
Source: Yahoo! Finance
therapies to treat immune-mediated diseases, today reported positive first-in-human study results and announced the close of an extension seed financing round, bringing the company's total funding to approximately $6 million. The funding follows the successful completion of a multi-center, single-blind, sham-controlled, cross-over study in 14 participants, including adults with inflammatory arthritis. The study demonstrated statistically significant reductions in key pro-inflammatory cytokines, including TNF-a and IL-6 - two key drivers of inflammation in autoimmune disease - compared with sham following repeated ultrasound stimulation, with no device-related adverse events reported. The company plans to publish data from the study later this year and present its findings at EULAR 2026. "Closing this financing on the back of positive first-in-human data is a milestone we're proud of – it reflects both the strength of the science and our team's ability to execute," said Nishant Doc
Show less
Read more
Impact Snapshot
Event Time:
RANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RANI alerts
High impacting Rani Therapeutics Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RANI
News
- Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
- Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer [Yahoo! Finance]Yahoo! Finance
- Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical OfficerGlobeNewswire
- Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
RANI
Earnings
- 8/7/25 - Beat
RANI
Analyst Actions
- 1/9/26 - HC Wainwright
RANI
Sec Filings
- 2/13/26 - Form SCHEDULE
- 2/12/26 - Form SCHEDULE
- 1/30/26 - Form SCHEDULE
- RANI's page on the SEC website